Oklahoma Attorney General Gentner Drummond is asking federal officials to address what he says are national security and consumer safety risks involving Chinese suppliers of pharmaceutical ingredients used in compounded GLP-1 drugs.
Drummond joined attorneys general from 19 other states in a letter to Secretary of State Marco Rubio raising concerns about ingredients used in compounded drugs including semaglutide, tirzepatide and retatrutide. The coalition is asking Rubio and the National Security Council to increase oversight of the FDA’s Green List program or stop potentially dangerous ingredients from entering the United States.
“Chinese businesses have found and exploited a gap in the system that gives them a direct line to patients in the U.S. who use popular injectable prescription drugs,” Drummond said. “This exploitation not only poses risks to the health and safety of consumers, but it constitutes a national security risk.”
The attorneys general contend the Green List, created by the FDA in September 2025, has allowed some Chinese suppliers to ship unapproved products into the United States without detention or inspection.
The letter cites Harbin Jixianglong Biotech Co. as an example. According to the coalition, the Chinese company purchased knock-off semaglutide from a facility that was not registered with the FDA, then repackaged and relabeled the product before distributing it to the United States. The activity was discovered during an on-site inspection.
